In late December 2019, several local health facilities reported clusters of patients with pneumonia of unknown cause that were epidemiologically linked to a seafood and wet animal wholesale market in Wuhan, Hubei Province, China. It is now confirmed that the etiology of this outbreak is a novel coronavirus, namely, 2019-nCoV. Of critical importance is rapid and simple diagnostic method to be used in clinical settings to timely inform and refine strategies that can prevent, control, and stop the spread of 2019-nCoV. Recombinase aided amplification (RAA) assay is a novel isothermal nucleic acid amplification technique in recent years, which has a variety of the advantages including high specificity and sensitivity, rapid detection (30 min), low cost, low equipment requirements and simple operation. The has successfully detected a variety of pathogens using this technique. To develop a RAA assay for 2019-nCoV with the advantages of high speed, simple operation and low cost, and overcomes the shortcomings of the existing molecular detection methods. The investigators established a real time reverse-transcription RAA (RT-RAA) assay for detection of 2019-nCoV. This assay was performed at 42°C within 30min using a portable real-time fluorescence detector, Recombinant plasmids containing conserved ORF1ab genes was used to analyze the specificity and sensitivity. Clinical specimens from patients who were suspected of being infected with 2019-nCoV were used to evaluate the performance of the assay. In parallel, The investigators also used the commercial RT-qPCR assay kit for 2019-nCoV as a reference.
In late December 2019, several local health facilities reported clusters of patients with
pneumonia of unknown cause that were epidemiologically linked to a seafood and wet animal
wholesale market in Wuhan, Hubei Province, China. It is now confirmed that the etiology of
this outbreak is a novel coronavirus, namely, 2019-nCoV. Of critical importance is rapid and
simple diagnostic method to be used in clinical settings to timely inform and refine
strategies that can prevent, control, and stop the spread of 2019-nCoV. Recombinase aided
amplification (RAA) assay is a novel isothermal nucleic acid amplification technique in
recent years, which has a variety of the advantages including high specificity and
sensitivity, rapid detection (30 min), low cost, low equipment requirements and simple
operation. The investigators has successfully detected a variety of pathogens using this
technique. To develop a RAA assay for 2019-nCoV with the advantages of high speed, simple
operation and low cost, and overcomes the shortcomings of the existing molecular detection
methods. The investigators established a real time reverse-transcription RAA (RT-RAA) assay
for detection of 2019-nCoV. This assay was performed at 42°C within 30min using a portable
real-time fluorescence detector, Recombinant plasmids containing conserved ORF1ab genes was
used to analyze the specificity and sensitivity. Clinical specimens from patients who were
suspected of being infected with 2019-nCoV were used to evaluate the performance of the
assay. In parallel, The investigators also used the commercial RT-qPCR assay kit for
2019-nCoV as a reference. Patients who were suspected of being infected with 2019-nCoV in the
hospital.
Diagnostic Test: Recombinase aided amplification (RAA) assay
We established a real time reverse-transcription RAA (RT-RAA) assay for detection of 2019-nCoV. This assay was performed at 42°C within 30min using a portable real-time fluorescence detector, Recombinant plasmids containing conserved ORF1ab genes was used to analyze the specificity and sensitivity. Clinical specimens from patients who were suspected of being infected with 2019-nCoV were used to evaluate the performance of the assay. In parallel, we also used the commercial RT-qPCR assay kit for 2019-nCoV as a reference. Sample types include either of nasal swab, oral swab, bronchoalveolar-lavage fluid, urea, blood, fecal.
Inclusion Criteria:
- 1. Suspected cases (formerly observed cases)
Meet the following 2 at the same time:
Epidemiological history There was a history of travel or residence in Wuhan within two
weeks before the onset of illness; or patients who had had fever from Wuhan with
respiratory symptoms within 14 days before the onset of illness, or had clustered onset.
Clinical manifestations
1. fever;
2. It has the imaging characteristics of pneumonia mentioned above;
3. The total number of white blood cells is normal or decreased, or the lymphocyte count
is decreased in the early stage of onset.
- 2. confirmed cases On the basis of meeting the criteria for suspected cases,
sputum, throat swabs, lower respiratory tract secretions, and other specimens
were tested by real-time fluorescent RT-PCR for positive nucleic acid detection
of new coronavirus; or viral gene sequencing was highly homologous with known new
coronaviruses.
Exclusion Criteria:
- 1. Influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus,
rhinovirus, human metapneumovirus, SARS coronavirus, and other known other viral
pneumonia;
- 2. Mycoplasma pneumoniae, chlamydia pneumonia, and bacterial pneumonia; non-infectious
diseases such as vasculitis, dermatomyositis, and organizing pneumonia.
Department of Hepatology Division 2, Beijing Ditan Hospital
Beijing, Beijing, China
Investigator: Yao Xie, Doctor
Contact: 8610-84322200
xieyao00120184@sina.com
Yao Xie, Doctor
8610-84322200 - 2489
xieyao00120184@sina.com
Xuejun Ma, phD
+86 10 58900810
maxj2004@aliyun.com
Yao Xie, Doctor, Principal Investigator
Department of Hepatology, Division 2, Beijing Ditan Hospital